SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-027967
Filing Date
2022-11-03
Accepted
2022-11-03 07:21:24
Documents
16
Period of Report
2022-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20221103.htm   iXBRL 8-K 40732
2 EX-99.1 a991pressreleasedatednovem.htm EX-99.1 97845
3 EX-99.2 a992pressreleasedatedoctob.htm EX-99.2 12743
7 x4logo.jpg GRAPHIC 4345
8 x4logoa.jpg GRAPHIC 4345
  Complete submission text file 0001628280-22-027967.txt   326171

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20221103.xsd EX-101.SCH 1908
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20221103_lab.xml EX-101.LAB 25948
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20221103_pre.xml EX-101.PRE 13681
10 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20221103_htm.xml XML 11883
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 221356211
SIC: 2836 Biological Products, (No Diagnostic Substances)